



Date: Wednesday, October 15, 2025

Time: 5:00 PM - 6:00 PM

Learning Format: Live Activity

Presentation Information:

- Nephrology Transplant Journal Club
 - Telitacicept's Impact on Recurrent IgA Nephropathy After Kidney Transplantation (Nephrology Transplant Journal Club - 10/15/2025)

Description:

Identify and discuss treatment expectations and updates on immunosuppressive regimens, pre-transplant management, and post-transplant comorbidities. Improve the overall clinical care and outcomes for nephrology transplant recipient candidates.

Series Objectives:

- 1 Utilizing cultural information to establish therapeutic patient relationships.
- 2 Apply linguistic skills to communicate effectively with the target population.
- 3 Understand and apply cultural and ethnic data to the process of clinical care.
- 4 Address quality assurance or improvement, risk management, health facility standards, and improve the physician-patient relationship.
- 5 Cite examples of how implicit bias affects perceptions and treatment decisions of physicians and surgeons, leading to disparities in health outcomes.
- 6 Understand and incorporate mitigation strategies to overcome implicit bias in patient care.

Session Objectives:

- 1 Discuss multi-hit model of IgA nephropathy pathogenesis
- 2 Discuss B-cell targeted therapy and telitacicept's mechanism of action
- 3 Explain the retrospective analysis and conclusions of the article and how this affects current practice methods

Accreditation Statement:

University of California, Davis Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

UC Davis Health designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

UC Davis Health designates this live activity for a maximum of 1.00 Participation Hour(s).

Mitigation Statement:

University of California, Davis Health Continuing Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of
--------------------	-------------------------------	-------------------------------------

		Ineligible Company(s)
Shelley Palumbo, MS, SLP	Other Planning Committee Member	Nothing to disclose - 09/18/2025
Ling-Xin Chen, MD	Course Director	Independent Contractor (included contracted research)-Transplant Genomics Independent Contractor (included contracted research)-MEMO Therapeutics Independent Contractor (included contracted research)-Veloxis Pharmaceuticals Independent Contractor (included contracted research)-Dexcom - 12/18/2024
Yihung Huang, MD	Course Director	Nothing to disclose - 10/06/2025
Marielle Llamas, MD, Physician	Faculty	Nothing to disclose - 01/16/2025

Commercial Support:

This activity is not commercially supported.